Antiplatelet drugs and gastrointestinal disorders: when and how effective are inhibitors of proton pump?


Cite item

Full Text

Abstract

Antiplatelet drugs are essential in current treatment of coronary heart disease (CHD) but they have an adverse action - damage to gastrointestinal mucosa. Long-term administration of several medicines in CHD patients makes possible interaction of some drugs. Clinical trials show that proton pump inhibitors (PPI) reduce frequency of recurrent gastrointestinal bleedings in patients of high cardiological risk on antiplatelet therapy. In prescription of PPI to CHD patients at high risk of gastropathy, it is necessary to consider both efficacy and safety of the drug.

About the authors

Oksana Mikhaylovna Drapkina

Email: drapkina@bk.ru

Ol'ga Nikolaevna Korneeva

O M Drapkina

I.M. Sechenov First Moscow State Medical University

I.M. Sechenov First Moscow State Medical University

O N Korneeva

I.M. Sechenov First Moscow State Medical University

I.M. Sechenov First Moscow State Medical University

References

  1. Антитромботическая терапия у больных со стабильными проявлениями атеротромбоза. Российские рекомендации. Кардиоваск. тер. и профилакт. 2009; Прил. 6.
  2. Cryer B., Feldman М. Effects of nonsteroidal anti-inflammatory drugs on endogenous gastrointestinal prostaglandins and therapeutic strategies for prevention and treatment of nonsteroidal, anti-inflammatory drug-induced damage. Arch. Intern. Med. 1992; 152: 1145-1155.
  3. Soli A. H., Weinstein W. M., Kurata J. et al. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann. Intern. Med. 1991; 114: 307.
  4. Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest. Endosc. Clin. N. Am. 1996; 6: 489-504.
  5. Bombardier C., Laine L., Reicin A. et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.VIGOR study group. N. Engl. J. Med. 2000; 343: 1520-1528.
  6. Peters R., Mehta S., Fox K. et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003; 108 (14): 1682-1687.
  7. Lame L. Review article: gastrointestinal bleeding with low-dose aspirin - what's the risk? Aliment Pharmacol Ther. 2006; 24: 897-908.
  8. Hallas J., Dall M., Andries A. et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. Br. Med. J. 2006; 333: 726.
  9. Lanza F., Chan F., Quigley E. Guidelines for prevention of NSAID-related ulcer complications. Am. J. Gastroenterol. 2009; 104: 728-738.
  10. Лапина Т. Л. Гастропатия, индуцированная нестероидными противовоспалительными препаратами: пути решения проблемы. Болезни органов пищевар. (прил. РМЖ) 2009; 2(11): 12-14.
  11. Rostom A., Wells G., Tugwell P. et al. The prevention of chronic NSAID induced upper gastrointestinal toxicity: a Cochrane collaboration metaanalysis of randomized controlled trials. J. Rheumatol. 2000; 27: 2203-2214.
  12. Lanas A., Garcia-Rodriguez L. A., Arroyo M. T. et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal antiinflammatory drugs, antiplatelet agents, and anticoagulants. Am. J. Gastroenterol. 2007; 102: 507-515.
  13. Bhatt D. L., Cryer B. L., Contant C. F. et al. Clopidogrel with or without omeprazole in coronary artery disease. N. Engl. J. Med. 2010; 363: 1909-1917.
  14. Bhatt D. L., Scheiman J., Abraham N. S. et al. ACCF/ACG/ AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J. Am. Coll. Cardiol. 2008; 52: 1502-1517.
  15. Явелов И. С. Роль двойной антитромбоцитарной терапии в консервативном лечении инфаркта миокарда. Клин. фармакол. и тер. 2010; 19(5): 23-32.
  16. Farid N. A., Kurihara A., Wrighton S. А. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J. Clin. Pharmacol. 2010; 50: 126-142.
  17. Roden D. M., Stein C. M. Clopidogrel and the concept of high-risk pharmacokinetics. Circulation 2009; 119: 2127- 2130.
  18. Shuldiner A. R., O'Connell J. R., Bliden K. P. et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009; 302:849-857.
  19. Abraham N., Hlatky M., Antman E. et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAIDUse. J. Am. Coll. Cardiol. 2010; 56: 2051- 2066.
  20. O'Donoghue M. L., Braunwald E., Antman E. M. et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009; 374: 989-997.
  21. Dunn S. P., Macaulay Т. Е., Brennan D. M. et al. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without use of clopidogrel in the CREDO trial. Circulation 2008; 118: S815.
  22. Ray W. A., Murray K. T., Griffin M. R. et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann. Intern. Med. 2010; 152: 337-345.
  23. Логинов А. Ф. Выбор ингибитора протонной помпы для профилактики и лечения НПВП-индуцированных поражений желудка. Клин. перспект. гастроэнтерол. и гепатол. 2009; 4: 13-21.
  24. Шарова Е. П. Препарат санпраз (пантопразол): опыт применения в лечении гастроэзофагеальной рефлюксной болезни и других кислотозависимых болезней. Экспер. и клин. гастроэнтерол. 2008; 06: 74-76.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies